MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) will report third quarter 2025 financial results before the market opens on Friday, November 14, 2025.

The company will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results, recent clinical progress and upcoming corporate milestones. MiNK recently presented late‑breaking data at the 2025 SITC Annual Meeting where its agenT-797 iNKT cell therapy showed durable immune reconstitution and signals of activity in patients with advanced solid tumors.

A live webcast and replay will be available from the company’s Events & Presentations page; dial‑in and webcast links are provided for investors.

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th.

The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.

MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, and upcoming corporate milestones.

Conference Participant Dial Information
United States - New York (646) 307-1963
USA & Canada - Toll-Free (800) 715-9871
Conference ID: 3474114

Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.

Live event link: https://edge.media-server.com/mmc/p/4bufw45x
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

Source: MiNK Therapeutics

FAQ

When will MiNK Therapeutics (INKT) release Q3 2025 financial results?

MiNK will release Q3 2025 results before the market opens on November 14, 2025.

What time is the MiNK (INKT) conference call and webcast for Q3 2025?

The conference call and webcast are scheduled for 8:30 a.m. ET on November 14, 2025.

What clinical data did MiNK (INKT) present at SITC 2025 about agenT-797?

MiNK presented data showing durable immune reconstitution and signals of activity for agenT-797 in advanced solid tumor patients.

How can investors access the MiNK (INKT) Q3 2025 webcast and replay?

A live webcast and replay will be accessible from MiNK’s Events & Presentations page on the company website; a live event link and replay are provided.

Will MiNK (INKT) discuss upcoming corporate milestones on the call?

Yes, company executives will discuss recent clinical progress and upcoming corporate milestones during the call.

What is agenT-797 mentioned in MiNK (INKT) materials?

agenT-797 is MiNK’s allogeneic iNKT cell therapy candidate being tested in patients with advanced solid tumors, as described in the SITC presentation.